Neumora Therapeutics (NMRA) Stock Forecast & Price Target

$12.90

+0.49 (+3.95%)

(As of 07/26/2024 ET)

Neumora Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 9 Analyst Ratings

Based on 9 Wall Street analysts who have issued ratings for Neumora Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 9 analysts, 1 has given a hold rating, and 8 have given a buy rating for NMRA.

Consensus Price Target

$22.33
73.13% Upside

High Forecast	$31.00
Average Forecast	$22.33
Low Forecast	$13.00

According to the 9 analysts' twelve-month price targets for Neumora Therapeutics, the average price target is $22.33. The highest price target for NMRA is $31.00, while the lowest price target for NMRA is $13.00. The average price target represents a forecasted upside of 73.13% from the current price of $12.90.

Type	Current Forecast 7/28/23 to 7/27/24	1 Month Ago 6/28/23 to 6/27/24	3 Months Ago 4/29/23 to 4/28/24	1 Year Ago 7/28/22 to 7/28/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	N/A
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	N/A
Buy	8 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)	N/A
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	N/A
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	N/A
Consensus Price Target	$22.33	$22.57	$22.57	N/A
Forecasted Upside	73.13% Upside	79.27% Upside	79.27% Upside	N/A

Get Neumora Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter.

Ad Colonial Metals

Collapse of the Petrodollar

The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.

In answer to this issue, we have released a Special Report to the public.

NMRA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NMRA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Neumora Therapeutics Stock vs. The Competition

Type	Neumora Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.89	2.72	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	73.13% Upside	3,123.40% Upside	9.10% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
7/22/2024	Needham & Company LLC 3 of 5 stars	A. Fadia Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$23.00	+103.90%
7/8/2024	Mizuho 2 of 5 stars	G. Suvannavejh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$20.00	+95.12%
4/12/2024	William Blair 2 of 5 stars	M. Minter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
3/28/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$31.00	+140.31%
3/18/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$20.00 ➝ $22.00	+55.15%
12/12/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold	$13.00	+0.23%
10/10/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$18.00	+50.75%
10/10/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$22.00	+84.25%
10/10/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$26.00	+117.76%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 07:11 AM ET.

NMRA Forecast - Frequently Asked Questions

What is Neumora Therapeutics' forecast for 2024?: According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Neumora Therapeutics is $22.33, with a high forecast of $31.00 and a low forecast of $13.00.
Should I buy or sell Neumora Therapeutics stock right now?: 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neumora Therapeutics in the last twelve months. There is currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NMRA shares.
Does Neumora Therapeutics's stock price have much upside?: According to analysts, Neumora Therapeutics's stock has a predicted upside of 83.64% based on their 12-month stock forecasts.
What analysts cover Neumora Therapeutics?: Neumora Therapeutics has been rated by research analysts at Mizuho, and Needham & Company LLC in the past 90 days.
Do Wall Street analysts like Neumora Therapeutics more than its competitors?: Analysts like Neumora Therapeutics more than other "medical" companies. The consensus rating score for Neumora Therapeutics is 2.89 while the average consensus rating score for "medical" companies is 2.72. Learn more on how NMRA compares to other companies.